Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
Chinook Therapeutics 7.83M share Secondary priced at $14.00 » 20:39
11/09/21
11/09
20:39
11/09/21
20:39
KDNY

Chinook Therapeutics

$14.55 /

+0.39 (+2.75%)

The deal size was…

The deal size was increased to 7.83M shares from 6.0M and priced below last closing price of $14.51. SVB Leerink and Evercore ISI are acting as joint book running managers for the offering.

ShowHide Related Items >><<
KDNY Chinook Therapeutics
$14.55 /

+0.39 (+2.75%)

KDNY Chinook Therapeutics
$14.55 /

+0.39 (+2.75%)

04/05/21 H.C. Wainwright
Chinook spinoff 'prudent way' to maximize Aduro value, says H.C. Wainwright
03/30/21 Cantor Fitzgerald
Cantor says Chinook BION-1301 abstract suggests positive proof of concept
01/06/21
Fly Intel: Top five analyst initiations
01/06/21 Wedbush
Wedbush bullish on Chinook Therapeutics, initiates with an Outperform
KDNY Chinook Therapeutics
$14.55 /

+0.39 (+2.75%)

  • 10
    Nov
Syndicate
Chinook Therapeutics announces offering of 6M shares of common stock » 16:03
11/08/21
11/08
16:03
11/08/21
16:03
KDNY

Chinook Therapeutics

$13.96 /

-1.99 (-12.48%)

Chinook Therapeutics…

Chinook Therapeutics announced that it intends to offer and sell 6M shares of its common stock in an underwritten public offering. Chinook intends to use the net proceeds from this offering to advance the phase 3 ALIGN trial of atrasentan in patients with IgA nephropathy and the phase 2 AFFINITY basket trial of atrasentan in patients with proteinuric glomerular diseases, initiate later-stage clinical development of BION-1301 for IgAN, move forward the development of CHK-336 for hyperoxalurias and continue progress on research and discovery programs. The remainder of the net proceeds, if any, will be used for general corporate purposes. SVB Leerink and Evercore ISI are acting as joint book-running managers for the proposed offering. Oppenheimer & Co., Wedbush PacGrow, and H.C. Wainwright & Co. are acting as lead managers for the proposed offering.

ShowHide Related Items >><<
KDNY Chinook Therapeutics
$13.96 /

-1.99 (-12.48%)

KDNY Chinook Therapeutics
$13.96 /

-1.99 (-12.48%)

04/05/21 H.C. Wainwright
Chinook spinoff 'prudent way' to maximize Aduro value, says H.C. Wainwright
03/30/21 Cantor Fitzgerald
Cantor says Chinook BION-1301 abstract suggests positive proof of concept
01/06/21
Fly Intel: Top five analyst initiations
01/06/21 Wedbush
Wedbush bullish on Chinook Therapeutics, initiates with an Outperform
KDNY Chinook Therapeutics
$13.96 /

-1.99 (-12.48%)

Hot Stocks
Chinook Therapeutics announces upcoming milestones » 08:07
11/08/21
11/08
08:07
11/08/21
08:07
KDNY

Chinook Therapeutics

$15.95 /

+3.69 (+30.10%)

Atrasentan: Enrollment of…

Atrasentan: Enrollment of the phase 3 ALIGN trial of atrasentan continues to progress with the activation of new trial sites and expansion into additional countries. Chinook expects to report topline data from the six-month interim proteinuria endpoint analysis in 2023 to support an application for accelerated approval under Subpart H in the U.S. Chinook continues to enroll all four cohorts of the phase 2 AFFINITY basket trial, including patients with lower proteinuria IgAN, focal segmental glomerulosclerosis, Alport syndrome and diabetic kidney disease in combination with SGLT2 inhibitors. Chinook expects to present data from the IgAN patient cohort of this study in the first half of 2022, with data from one or more additional cohorts expected in the second half of 2022. BION-1301: Chinook expects to present additional data from the ongoing phase 1/2 trial of BION-1301 in patients with IgAN and provide an update on planned later-stage clinical trials of BION-1301 in the first half of 2022. CHK-336: Chinook has completed IND-enabling toxicology studies and is advancing CHK-336 towards IND submission and initiation of a phase 1 clinical trial in healthy volunteers in the first half of 2022.

ShowHide Related Items >><<
KDNY Chinook Therapeutics
$15.95 /

+3.69 (+30.10%)

KDNY Chinook Therapeutics
$15.95 /

+3.69 (+30.10%)

04/05/21 H.C. Wainwright
Chinook spinoff 'prudent way' to maximize Aduro value, says H.C. Wainwright
03/30/21 Cantor Fitzgerald
Cantor says Chinook BION-1301 abstract suggests positive proof of concept
01/06/21
Fly Intel: Top five analyst initiations
01/06/21 Wedbush
Wedbush bullish on Chinook Therapeutics, initiates with an Outperform
KDNY Chinook Therapeutics
$15.95 /

+3.69 (+30.10%)

Earnings
Chinook Therapeutics reports Q3 EPS (69c), consensus (84c) » 08:07
11/08/21
11/08
08:07
11/08/21
08:07
KDNY

Chinook Therapeutics

$15.95 /

+3.69 (+30.10%)

Reports Q3 revenue…

Reports Q3 revenue $4,000, consensus $40,000. Cash, cash equivalents and marketable securities totaled $204.8M at September 30, 2021, compared to $250.4 million at December 31, 2020. "During the third quarter of 2021, we focused on execution and advancement of our lead clinical programs, atrasentan and BION-1301 for IgA nephropathy, a serious progressive disease for which there are no approved therapies. We are advancing enrollment in the ALIGN and AFFINITY studies of atrasentan, and the data we recently presented at ASN from the ongoing phase 1/2 study of BION-1301 in patients with IgAN shows consistent mechanistic biomarker responses and clinically meaningful reductions in proteinuria within three months of initiating treatment, demonstrating its potential as a novel disease-modifying therapy," said Eric Dobmeier, president and chief executive officer of Chinook Therapeutics. "We're enthusiastic about the potential of precision medicine to provide new treatments for kidney disease, and we look forward to continuing to advance our other pipeline programs, including initiating a phase 1 study of CHK-336 next year and making progress on our research and discovery programs."

ShowHide Related Items >><<
KDNY Chinook Therapeutics
$15.95 /

+3.69 (+30.10%)

KDNY Chinook Therapeutics
$15.95 /

+3.69 (+30.10%)

04/05/21 H.C. Wainwright
Chinook spinoff 'prudent way' to maximize Aduro value, says H.C. Wainwright
03/30/21 Cantor Fitzgerald
Cantor says Chinook BION-1301 abstract suggests positive proof of concept
01/06/21
Fly Intel: Top five analyst initiations
01/06/21 Wedbush
Wedbush bullish on Chinook Therapeutics, initiates with an Outperform
KDNY Chinook Therapeutics
$15.95 /

+3.69 (+30.10%)

Conference/Events
Chinook Therapeutics to host conference call » 16:25
11/04/21
11/04
16:25
11/04/21
16:25
KDNY

Chinook Therapeutics

$12.26 /

+1.025 (+9.12%)

Conference call to…

Conference call to discuss data presented at ASN Kidney Week 2021 to be held on November 4 at 4:30 pm. Webcast Link

ShowHide Related Items >><<
KDNY Chinook Therapeutics
$12.26 /

+1.025 (+9.12%)

KDNY Chinook Therapeutics
$12.26 /

+1.025 (+9.12%)

04/05/21 H.C. Wainwright
Chinook spinoff 'prudent way' to maximize Aduro value, says H.C. Wainwright
03/30/21 Cantor Fitzgerald
Cantor says Chinook BION-1301 abstract suggests positive proof of concept
01/06/21
Fly Intel: Top five analyst initiations
01/06/21 Wedbush
Wedbush bullish on Chinook Therapeutics, initiates with an Outperform
KDNY Chinook Therapeutics
$12.26 /

+1.025 (+9.12%)

Conference/Events
Chinook Therapeutics to host conference call » 04:55
11/04/21
11/04
04:55
11/04/21
04:55
KDNY

Chinook Therapeutics

$11.19 /

+0.09 (+0.81%)

Conference call to…

Conference call to discuss data presented at ASN Kidney Week 2021 to be held on November 4 at 4:30 pm. Webcast Link

ShowHide Related Items >><<
KDNY Chinook Therapeutics
$11.19 /

+0.09 (+0.81%)

KDNY Chinook Therapeutics
$11.19 /

+0.09 (+0.81%)

04/05/21 H.C. Wainwright
Chinook spinoff 'prudent way' to maximize Aduro value, says H.C. Wainwright
03/30/21 Cantor Fitzgerald
Cantor says Chinook BION-1301 abstract suggests positive proof of concept
01/06/21
Fly Intel: Top five analyst initiations
01/06/21 Wedbush
Wedbush bullish on Chinook Therapeutics, initiates with an Outperform
KDNY Chinook Therapeutics
$11.19 /

+0.09 (+0.81%)

Conference/Events
Chinook Therapeutics to host conference call » 16:43
10/29/21
10/29
16:43
10/29/21
16:43
KDNY

Chinook Therapeutics

$10.75 /

+ (+0.00%)

Conference call to…

Conference call to discuss data presented at ASN Kidney Week 2021 to be held on November 4 at 4:30 pm. Webcast Link

ShowHide Related Items >><<
KDNY Chinook Therapeutics
$10.75 /

+ (+0.00%)

KDNY Chinook Therapeutics
$10.75 /

+ (+0.00%)

04/05/21 H.C. Wainwright
Chinook spinoff 'prudent way' to maximize Aduro value, says H.C. Wainwright
03/30/21 Cantor Fitzgerald
Cantor says Chinook BION-1301 abstract suggests positive proof of concept
01/06/21
Fly Intel: Top five analyst initiations
01/06/21 Wedbush
Wedbush bullish on Chinook Therapeutics, initiates with an Outperform
KDNY Chinook Therapeutics
$10.75 /

+ (+0.00%)

Over a month ago
Conference/Events
Chinook Therapeutics participates in a conference call with Wedbush » 09:25
10/25/21
10/25
09:25
10/25/21
09:25
KDNY

Chinook Therapeutics

$10.87 /

-0.05 (-0.46%)

Biotech Analysts…

Biotech Analysts Nierengarten & Chico hold a conference call with President & CEO Dobmeier and CFO Bjerkholt on October 25 at 10 am.

ShowHide Related Items >><<
KDNY Chinook Therapeutics
$10.87 /

-0.05 (-0.46%)

KDNY Chinook Therapeutics
$10.87 /

-0.05 (-0.46%)

04/05/21 H.C. Wainwright
Chinook spinoff 'prudent way' to maximize Aduro value, says H.C. Wainwright
03/30/21 Cantor Fitzgerald
Cantor says Chinook BION-1301 abstract suggests positive proof of concept
01/06/21
Fly Intel: Top five analyst initiations
01/06/21 Wedbush
Wedbush bullish on Chinook Therapeutics, initiates with an Outperform
KDNY Chinook Therapeutics
$10.87 /

-0.05 (-0.46%)

Conference/Events
Chinook Therapeutics participates in a conference call with Wedbush » 04:55
10/25/21
10/25
04:55
10/25/21
04:55
KDNY

Chinook Therapeutics

$10.87 /

-0.05 (-0.46%)

Biotech Analysts…

Biotech Analysts Nierengarten & Chico hold a conference call with President & CEO Dobmeier and CFO Bjerkholt on October 25 at 10 am.

ShowHide Related Items >><<
KDNY Chinook Therapeutics
$10.87 /

-0.05 (-0.46%)

KDNY Chinook Therapeutics
$10.87 /

-0.05 (-0.46%)

04/05/21 H.C. Wainwright
Chinook spinoff 'prudent way' to maximize Aduro value, says H.C. Wainwright
03/30/21 Cantor Fitzgerald
Cantor says Chinook BION-1301 abstract suggests positive proof of concept
01/06/21
Fly Intel: Top five analyst initiations
01/06/21 Wedbush
Wedbush bullish on Chinook Therapeutics, initiates with an Outperform
KDNY Chinook Therapeutics
$10.87 /

-0.05 (-0.46%)

Conference/Events
Chinook Therapeutics participates in a conference call with Wedbush » 15:10
10/19/21
10/19
15:10
10/19/21
15:10
KDNY

Chinook Therapeutics

$11.54 /

-0.02 (-0.17%)

Biotech Analysts…

Biotech Analysts Nierengarten & Chico hold a conference call with President & CEO Dobmeier and CFO Bjerkholt on October 25 at 10 am.

ShowHide Related Items >><<
KDNY Chinook Therapeutics
$11.54 /

-0.02 (-0.17%)

KDNY Chinook Therapeutics
$11.54 /

-0.02 (-0.17%)

04/05/21 H.C. Wainwright
Chinook spinoff 'prudent way' to maximize Aduro value, says H.C. Wainwright
03/30/21 Cantor Fitzgerald
Cantor says Chinook BION-1301 abstract suggests positive proof of concept
01/06/21
Fly Intel: Top five analyst initiations
01/06/21 Wedbush
Wedbush bullish on Chinook Therapeutics, initiates with an Outperform
KDNY Chinook Therapeutics
$11.54 /

-0.02 (-0.17%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.